Gold standard in anticoagulation assessment of left ventricular assist device patients?: how about bronze

Affiliations

¹ Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah. Electronic address: josef.stehlik@hsc.utah.edu.
² Department of Internal Medicine, Thrombosis Service, University of Utah School of Medicine, Salt Lake City, Utah.
³ Division of Cardiothoracic Surgery, University of Utah School of Medicine, Salt Lake City, Utah.

Free article

Editorial

Josef Stehlik et al. JACC Heart Fail. 2015 Apr.

Free article

. 2015 Apr;3(4):323-6.

doi: 10.1016/j.jchf.2015.01.004. Epub 2015 Mar 11.

¹ Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah. Electronic address: josef.stehlik@hsc.utah.edu.
² Department of Internal Medicine, Thrombosis Service, University of Utah School of Medicine, Salt Lake City, Utah.
³ Division of Cardiothoracic Surgery, University of Utah School of Medicine, Salt Lake City, Utah.

No abstract available

Keywords: bleeding; heart failure; heparin; left ventricular assist device; systemic anticoagulation.

Comment on

Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
Adatya S, Uriel N, Yarmohammadi H, Holley CT, Feng A, Roy SS, Reding MT, John R, Eckman P, Zantek ND. Adatya S, et al. JACC Heart Fail. 2015 Apr;3(4):314-22. doi: 10.1016/j.jchf.2014.11.009. Epub 2015 Mar 11. JACC Heart Fail. 2015. PMID: 25770404